UPC_CFI_123/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Einstweilige MaßnahmenEinstweilige MaßnahmenHamburg LDProvisional measuresCase Closed

Übersicht Entscheidungen Begründung Zitate Dokumente Zeitverlauf

Parteien

Kläger

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Elena Hennecke

Beklagte

Samsung Bioepis NL B.V.

Vertreter: Andrea Ritter

Richter

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patente

EP3167888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

PI abgelehnt

Eingereicht: 19. März 2024

Erste Entscheidung: 26. Juni 2024

Sprache: English

The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against Samsung Bioepis based on EP 3 167 888, finding that while direct infringement could be established, the court could not be sufficiently certain of the patent's validity given the EPO Technical Board of Appeal's history of rejecting correction requests for SEQ ID NO:4, and thus denied the measure.

Im UPC-Register öffnen